Latest News

May 26, 2010

Health Enhancement Products Announces Details of Its June 8th Scientific Panel Presentation

May 11, 2010

Health Enhancement Products Schedules Press Event June 8 to Present Breakthroughs in Its Cholesterol Management Research

April 26, 2010

Health Enhancement Products Secures Funding Enabling the Company to Begin Phase O Clinical Trials

April 21, 2010

Health Enhancement Products Names Denis M. Callewaert, Ph.D. to Its New Chief Science Officer Position

April 13, 2010

Professor of Molecular Toxicology at Penn State University, Jack Vanden Heuvel PhD, to Join Health Enhancement Products Scientific Advisory Boardt

March 9, 2010

Wayne State University Researchers Discover Potentially New Means to Regulate Bad Cholesterol and Raise HDL (Good Cholesterol) With Bioactive Molecules Derived From ProAlgaZyme(TM) -- a Proprietary Algal Extract

July 20, 2010

Health Enhancement Products Expands Scientific Advisory Board Dr. Donald Armstrong, Noted Expert in Oxidative Stress and Inflammation, Joins as Science Advisor

 


Health Enhancement Products is a member of these organizations







 
Health Enhancement Products Retains Intellectual Property Law Experts Kohn & Associates pllc

The Kohn Firm is Internationally Recognized as One of the Foremost IP firms Specializing in Biotechnology and Many of Their Representative Clients are the World's Major Pharmaceutical Companies

Press Release Source: Health Enhancement Products, Inc.
Wednesday February 10, 2010, 8:00 am EST

 

SCOTTSDALE, Ariz., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI - News) (HEPI) today announced it has retained the services of Kohn & Associates for intellectual property law representation.

Founded in 1995, Kohn & Associates is a group of highly dedicated professionals with diverse scientific and legal acumen. Recognized nationally for their expertise, experience, and effectiveness as a versatile intellectual property law firm, they possess a wealth of experience in the areas of utility and design patents, trademarks, copyrights, opinion work and due diligence, licensing, trade secrets, and litigation.

Kohn & Associates has been internationally recognized as one of the foremost IP firms specializing in biotechnology. As true pioneers in the field, they have been recognized by the National Institutes of Health as one of the top twelve (12) firms worldwide specializing in biotechnology patent prosecution. These rankings were the product not only of their technical expertise in technologies and intellectual property issues, but also based on their proposal for partnering with the NIH in its case management approach.

The Company's biotech clients span the full spectrum of innovative settings: from prestigious research universities and institutions, to Fortune 500 (R) corporations, to start-ups. They have represented inventors considered pioneers in their respective scientific disciplines, and successfully prosecuted applications for cutting-edge therapies, treatments, and procedures. A brief list of their representative clients can be found at http://www.kohnandassociates.com/cms--representative-clients.html.

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB:HEPI - News) is a health & wellness company engaged in the development of a product comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme (R) (PAZ(TM)) a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme (R).

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit http://www.heponline.com.

Contact:

American Capital Ventures
IR Contact:
Howard Gostfrand
David Sasso
305.918.7000
info@amcapventures.com
www.amcapventures.com

<< Back to Releases

 

© 2009 HEALTH ENHANCEMENT PRODUCTS INC.
            PRIVACY POLICY           DISCLAIMER